Navigator Medicines has raised USD 100 million in a Series A funding round led by RA Capital Management and Forbion.
The funds raised will be used to in-license NAV-240 and an OX40L-targeted portfolio from IMBiologics. NAV-240, formerly known as IMB101, is a bispecific antibody against OX40L and TNFα, two clinically validated inflammatory disease targets.
Navigator Medicines, a subsidiary of Sera Medicines, is a biotech company focused on developing biologics for targeted immune regulation and restoration. The company primarily focuses on creating new therapies for patients with complex, heterogeneous autoimmune diseases. Its lead product candidate is NAV-240, a clinical-stage bispecific antibody targeting OX40L and TNFα, two clinically validated targets critical in the pathogenesis of several inflammatory diseases. This dual-targeting approach aims to develop therapies for complex autoimmune conditions with unmet medical needs.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.